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ABSTRACT
To determine the prevalence of dementia associated with Parkinson’s disease (PD-D) 
in a Brazilian sample adopting clinical and diagnostic procedures recommended by the 
Movement Disorders Society (MDS). Sixty-seven patients were consecutively submitted 
to neurological, neuropsychological and functional examinations. PD-D was established 
according to MDS clinical criteria (Level II) and clinical procedures for PD-D (Level I) and 
prevalence rate was compared between the levels adopted. Ten patients (14.9%) were 
diagnosed as demented by Level I criteria whereas sixteen (23.8%) were diagnosed based 
on Level II criteria. Level I criteria had low sensitivity in detecting PD-D (31.25%), but 
greater specificity (90.19). The PD-D group had significantly worse performance  on all 
neuropsychological tests, were older (p<0.001), had an older age of onset ofdisease (p<0.01), 
had lower educational level (p<0.02) and had higher scores on functional scales. Current 
age (p=0.046) and Hoehn & Yahr score (p=0.048) were predictors for developing PD-D. 
Key words: Parkinson’s disease, Parkinson’s disease dementia, neuropsychological 
evaluation.
Prevalência da demência associada à doença de Parkinson: uma amostra brasileira
RESUMO
Determinar a prevalência de demência associada à doença de Parkinson (D-DP) em uma 
amostra brasileira, adotando os procedimentos diagnósticos e clínicos recomendados 
pela Movement Disorders Society (MDS). Sessenta e sete pacientes foram submetidos à 
avaliação neurológica, neuropsicológica e funcional. D-DP foi estabelecida de acordo com 
os procedimentos (Nível I) e critérios clínicos propostos pela MDS (Nível II) e a prevalência 
de D-DP foi comparada entre os níveis adotados. A prevalência de D-DP encontrada pelo 
Nível I e II, foi de 14,9% e 23,8%, respectivamente. O Nível I apresentou baixa sensibilidade 
em detectar D-DP (31,25%), porém, mostrou alta especificidade (90,19%). O grupo D-DP 
teve desempenho significativamente inferior em todas tarefas neuropsicológicas, eram 
mais velhos (p<0,001), mais velhos ao início da doença (p<0,01), menos escolarizados 
(p<0,02) e elevados escores nas tarefas funcionais. Idade atual (p=0,046) e escore no 
Hoehn & Yahr (p=0,048) foram apontados como preditores do desenvolvimento de D-DP. 
Palavras-Chave: doença de Parkinson, demência associada à doença de Parkinson, 
avaliação neuropsicológica.
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Despite the fact that Parkinson’s disease 
(PD) is known as a motor disease, it has 
been increasingly recognized as also con-
sisting of cognitive1,2 deficits are common 
even in early and newly diagnosed PD3. 
Parkinson’s disease patients have an al-
most sixfold increased risk of developing 
dementia compared to healthy controls 
and 3-4% of dementia cases in the general 
population are due to PD2. Risk factors for 
development of dementia associated with 
Parkinson’s disease (PD-D) include in-
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creasing age, older age at onset of disease, longer dis-
ease duration, severity of parkinsonism, male gender and 
presence of psychiatric symptoms4. 
The incidence and prevalence rates of PD-D are con-
troversial, and it could be attributed to differing methods 
used to define PD-D5 and to the fact that there is a lack 
of specific criteria for clinical diagnosis of PD-D. In an 
effort to minimize the wide variations of PD-D preva-
lence, the Movement Disorder Society Task Force on De-
mentia in Parkinson’s Disease (MDS) published clinical 
diagnostic criteria for “probable” and “possible” PD-D5. 
They also developed diagnostic procedures for PD-D6 
with two levels of assessment. In diagnostic procedure 
Level I, a brief screening tool is conducted by a physi-
cian to diagnose PD-D, whereas Level II diagnosis con-
sists of an extensive neuropsychological battery of tests 
that could determine severity of cognitive impairments. 
Because these diagnostic procedures for PD-D have been 
proposed recently, their sensitivity and specificity in de-
tecting PD-D are still unknown. 
The aim of this study was to compare the prevalence 
of dementia associated with Parkinson’s disease using 
clinical5 and diagnostic procedures6 and the criteria rec-
ommended by the MDS task force for PD-D. Further-
more, we wanted to determine the prevalence rates and 
predictors of PD-D in a Brazilian sample.
METHOD
Ninety patients who fulfilled our inclusion criteria 
and provided written informed consent (by their rela-
tives in PD-D or in illiterate patients) were enrolled in 
the study. The study was approved by the local ethics 
committee. All patients were consecutively recruited 
from the Neurology Service of Hospital Santa Marce-
lina in São Paulo. All patients fulfilled criteria for Par-
kinson’s disease according to the United Kingdom Par-
kinson’s Disease Society Brain Bank7. PD patients were 
submitted to demographic and neurological evaluations. 
Demographic data included age at onset of disease, du-
ration of disease (determined by years since onset of dis-
ease), drug treatment and years of schooling. 
Exclusion criteria included major depression (mea-
sured by beck depression inventory (BDI) score >19)8, 
vascular events, concomitant severe or uncontrolled 
chronic illness, pharmacological effect (e.g., dopamine 
antagonists), uncorrected visual or hearing impairment 
and refusal to participate in the study. Illiteracy was not 
included in the exclusion criteria. Moreover, all patients 
who completed at least 75% of neuropsychological bat-
tery were included. 
Functional assessment
Activities of daily living (ADL) were evaluated using 
Disability Assessment of Dementia (DAD)9 and Pill 
Questionnaire6 scores. The DAD scale evaluates the pa-
tient’s capacity to perform basic ADL (dressing, hygiene, 
continence and eating), instrumental activities (meal 
preparation, telephoning, housework, taking care of fi-
nances and correspondences, going on an outing, taking 
medications and being able to stay safe at home) and lei-
sure activities within the past four weeks. The DAD scale 
also investigates the degree of complexity of behavior or 
independence (initiation, planning, organization and ef-
fective action) by the patient. The Pill Questionnaire was 
proposed as a diagnostic procedure to assess functional 
impairment by the MDS task force on PD-D6 and re-
fers to questions asked to the patient and their caregiver 
about the ability to independently organize their daily 
distribution of antiparkinsonian medications. 
The neurological assessment integrated two clinical 
scales to determine the severity of PD: Hoehn & Yahr 
staging10 and Unified Parkinson Disease Rating Scale 
(UPDRS)11. Functional disability was evaluated by the 
Schwab and England scale12.
Neuropsychological assessment
The neuropsychological assessment battery included 
screening tools (Mini Mental State Examination (MMSE) 
and Beck Depression Inventary)13,14, short-term and 
working memory for verbal and spatial materials (Digit 
span15, Corsi blocks tapping, forward span and backward 
span16), episodic memory (Logical Memory, Visual Re-
production17, Figure Complex of Rey18 and Rey Audi-
tory Verbal Learning tests (RAVLT)19), executive func-
tions (Trail Making part B20, Frontal Assessment Battery 
(FAB)21, Phonemic Fluency verbal and FAS22), attention 
(Trail Making part A)23 and semantic fluency verbal24. 
To avoid fatigue in the PD patients, neuropsycholog-
ical assessment was conducted over two visits, each one 
lasting approximately one and a half hours in duration. 
Due to dyskinesia or illiteracy, some patients were un-
able to complete all tests.
Procedure
Each patient was submitted to neurological and neu-
ropsychological assessments by independent raters who 
were blind to the results obtained in each other’s evalua-
tion. The results from the neuropsychological tests were 
used to subdivide the sample using both diagnostic pro-
cedures (Level I)6 and clinical criteria (Level II)5 recom-
mended by the MDS task force for PD-D.
Classification of the sample using  
clinical diagnostic criteria for PD-D (Level II)
A diagnosis of PD-D was established if: [A] dementia 
developed after the diagnosis of idiopathic PD; [B] there 
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was a presence of cognitive deficits in at least two cogni-
tive domains (including memory impairment); [C] cogni-
tive impairment was severe enough to affect premorbid 
level; [D] deficits were severe enough to impair daily life 
independent of the impairment explained by motor or 
autonomic symptoms and [E] the cognitive and behav-
ioral symptoms were not better explained by other con-
ditions or diseases. The patient was classified with im-
paired cognition if performance scores were lower than 
1.5 SD below the Brazilian normative data (available to 
MMSE, FAB, RAVLT, semantic and phonemic fluency 
verbal tests) in at least two cognitive domains, being that 
abnormal performance in a single test represents cogni-
tive function impairment. 
Classification of the sample using  
diagnostic procedures for DP-D (Level I)
A diagnosis of PD-D was given if PD developed prior 
to the onset of dementia, MMSE <26, cognitive impair-
ment impacted daily living (measured by the Pill Ques-
tionnaire), and patients had impairment in at least two 
of following tests: seven backwards, pentagons and word 
recall (MMSE subtests) and lexical fluency.
Data analysis
Differences in demographic and clinical characteris-
tics between PD and PD-D groups were analyzed with de-
scriptive statistics. The Mann-Whitney test was used to 
compare performance between groups on cognitive tests.
Logistic regression analyses were used to identify age, 
Hoehn & Yahr scores and years of schooling as predic-
tors of developing PD-D. All analyses were performed 
using Statistics 6.0 software, and p values were calcu-
lated at the 0.05 significance level.
RESULTS 
From the ninety PD patients consecutively enrolled 
in this study, twenty-three patients (25%) was excluded 
because they fulfilled depression criteria or had difficul-
ties in filling out at least 75% of the cognitive assessment 
due to illiteracy or dyskinesia. Demographics, clinical 
characteristics and cognitive performance on neuropsy-
chological tests from the overall sample and from PD 
or PD-D subgroups defined by diagnostic procedures 
and clinical criteria (Levels I and II) for PD-D are shown 
in Table. 
We found that 23.8% (16 patients) of the demented 
patients met the clinical MDS diagnostic criteria for 
PD-D. The PD-D group had lower number of years of 
schooling (U=189.00, p=0.001), was older (U=189.50, 
p=0.001) and was older at the onset of disease (U=191.00, 
p=0.001). Patients in this group also showed more se-
vere disease (Hoehn & Yahr, U=276.00, p=0.05) and 
lower independence on activities of daily living (Schwab 
and England scale, U=230.00, p=0.01). In a neuropsy-
chological assessment, the PD-D group had significantly 
lower performance on several measures, including the 
screening tool (MMSE, U=66.50, p<0.01) and verbal ep-
isodic memory tests (Logical Memory and RAVLT) for 
both immediate recall (U=113.00, U=219.50, respec-
tively; p’s<0.01) and delayed recall (U=97.50; U=167.50; 
p’s<0.01). The PD-D group also had poorer perfor-
mance on visual episodic memory tests (Figure Com-
plex of Rey and Visual Reproduction) on immediate 
recall (U=169.50, U=192.50, respectively; p’s<0.001), de-
layed recall (U=255.50; U=105.00; p’s<0.001), backwards 
spatial span (Corsi, U=186.00, p=0.002) and construc-
tive praxis (copy of Figure Complex of Rey, U=54.50; 
p=0.03). Poorer performances on cognitive tests that in-
volved speed processing (Stroop card I, U=49.00, p<0.01) 
and executive functions (Trail Making part B, U=32.50, 
p=0.03; Stroop card II, U=133.00, p=0.01) were also ob-
served in the PD-D group. 
The comparison between Level I and II diagnostic 
criteria showed that whereas clinical diagnostic cri-
teria (Level II) found a 23.8% (16 patients) PD-D preva-
lence rate, Level I diagnostic procedures found PD-D in 
14.9% (10 patients). Compared to PD patients without 
dementia as diagnosed by Level I criteria, the PD-D 
sample had poorer scores on the UPDRS factor I and II 
(U=131.00, U=138.50, respectively, p’s<0.02) and on the 
MMSE (U=83.50; p<0.01). Considering that Level I diag-
nostic criteria involves some items from the MMSE that 
can be influenced by the number of years of schooling, 
we reanalyzed the data, taking into account educational 
level cutoff scores from the MMSE subtests (impair-
ment on Serial 7’s changed from 2 incorrect answers to 
3, impairment on 3-word recall changed from 2 to 1 and 
missing word and drawing pentagons had no score al-
teration) and found that 49.2% (n=28) patients who were 
cognitively intact were reclassified as cognitively im-
paired. After reanalyzing the data with Brazilian cutoffs, 
we observed that the prevalence of dementia remained 
the same. The main reason that the prevalence of PD-D 
was unaltered may be that 8 patients who could be clas-
sified as demented were not classified as such because 
they did not have ADL impairment as measured by the 
Pill Questionnaire. However, all these patients had ADL 
impairment according to the DAD scale. 
Level I criteria had low sensitivity in detecting PD-D 
(31.25%), greater specificity (90.19%) and positive and 
negative predictive values of 50% and 82.45%, respectively.
Logistic regression analysis found that current age 
(p=0.046) and Hoehn & Yahr score (p=0.048) were 
predictors of developing of dementia associated with 
Parkinson’s disease.
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Table. Demographical and clinical data of the PD sample and performance on neuropsychological evaluation of PD and PD-D subgroups 
(Median±standard deviation).
PD patients
(n=67)
Diagnostic procedures 
for PD-D
Clinical diagnostic 
criteria for PD-D
P 
value*
PD NorCog
(n=57)
PD-D
(n=10)
PD NorCog 
(n= 51)
PD-D
(n=16)
Age, years 66.97±11.71* 65.60±11.55 74.8±9.77 64.37±11.24 75.25±9.27* 0.04
Female (%) 50.76 45.61 80 41.17 81.25
Years of schooling 4.72±3.60 5.35±3.50 1.10±1.37 5.51±3.72 2.18±1.42* 0.001
Illiterate (n) 6 1 5 4 2
Age at onset of disease 61.36±12.78 59.91±12.55 69.60±11.32 58.57±11.98 70.25±11.34* 0.001
Time of PD, years 6.08±4.90 6.36±5.04 4.50±3.87 6.32±4.78 3.75±3.33 0.28
UPDRS - Factor I 2.65±2.21 2.30±1.72 4.78±3.49 2.28±1.54 14.25±8.01 0.02
UPDRS - Factor II 12.81±6.97 12.20±6.92 16.44±6.48 12.32±6.60 27.62±12.92 0.03
UPDRS - Factor III 27.24±12.61 27.33±13.06 26.67±10.09 27.11±12.64 2.75±3.53 0.96
UPDRS - Factor IV 2.90±3.07 3.02±2.94 2.22±3.87 2.96±2.93 48.25±21.81 0.18
UPDRS - Total 45.79±20,28 45.09±20.53 50±19.29 44.96±19.91 66.25±18.57 0.46
Hoehn & Yahr 2.55±0.67 2.54±0.70 2.60±0.52 2.45±0.68 2.87±0.56 0.01
Scwhab and England 75.71±17.66 76.85±17.79 68.9±16.1 78.94±16.3 66. 25±18.57 0.01
DAD 72.92±6.74 72.92±6.74 66.44±5.59 74.59±4.69 64.37±6.90 0.00008
BDI 9.06±4.46 8.60±4.26 11.70±4.88 8.59±4.74 10.56±3.05 0.11
MMSE 23.28±4.13 24.16±3.40 18.40±4.55 24.70±3.10 18.53±3.58 0.0000
FAB 9.73±3.84 10.41±3.60 6.10±3.14 10.63±3.71 6.80±2.65 0.002
Logical memory immediate recall 13.52±8.96 14.55±9.00 7.44±6.11 16.15±8.80 5.93±3.37 0.0000
Logical memory delayed recall 8.84±8.29 9.74±8.34 3.44±5.72 11.28±8.15 1.68±2.65 0.0000
RAVLT - ∑ A1-A5 26.62±9.34 27.41±9.15 21.89±9.62 28.69±8.92 20.00±7.58 0.008
RAVLT - list B 2.77±1.81 2.81±1.91 2.50±1.18 3.08±1.77 1.73±1.57 0.01
RAVLT - immediate recall 4.39±2.83 4.67±2.73 2.9±3.07 4.85±2.91 2.86±1.92 0.01
RAVLT - delayed recall 4.30±2.78 4.57±2.74 2.80±2.62 5.10±2.38 1.66±2.35 0.00006
FCR - copy 27.57±14.99 28.42±15.07 15.67±7.57 28.89±15.25 18.91±10.20 0.03
FCR - immediate recall 10.19±7.09 10.40±7.21 7.17±5.20 11.08±6.97 5.35±6.08 0.04
FCR - delayed recall 4.30±2.78 9.10±6.86 8.83±3.33 10.09±6.29 3.57±6.24 0.01
Visual reproduction - immediate 15.85±10.65 17.10±10.63 7.42±6.29 18.82±10.22 7.35±6.64 0.0002
Visual reproduction - delayed recall 9.19±9.54 10.44±9.67 1.14±1.21 11.57±9.83 2.71±4.51 0.0008
Digit span forward 4.96±1.17 5.08±1.16 4.22±0.97 5.12±1.17 4.5±1.09 0.06
Digit span backward 2.90±1.09 3.03±0.96 2.11±1.53 3.06±1.01 2.43±1.20 0.12
Corsi - forward 3.79±1.06 3.83±1.02 3.50±0.92 3.83±1.08 3.66±0.72 0.39
Corsi - backward 2. 98±1.209 3.16±1.14 1.75±1.66 3.24±1.19 8.18±3.05 0.002
Semantic fluency verbal 11.12±3.53 11.53±3,35 8.55±3.74 12.08±3.14 8.18±3.05 0.000
Phonemic fluency verbal (FAS) 20.83±10.32 21.21±10.22 2.3±9.82 13.08±8.40 0.003
TMT part A 135.30±101.47 127.62±93.82 289.00±171.11 124.19±95.53 202.0±119 0.07
TMT part B 290.78±180.13 286.62±180.74 445.00 258.30±147.86 505.20±243.00 0.03
Stroop card I 26.17±9.97 26.17±9.97 51.66±11.67 23.57±7.79 41.66±11.82 0.0000
Stroop card II 39.86±21.78 39.86±21.78 75.66±29.56 36.02±14.31 62.25±36.04 0.01
Stroop card III 57.78±33.55 57.58±33.55 66.00±19.79 51.42±21.90 82.63±53.53 0.06
Values are mean±SD. *Mann-Whitney U test. PD: Parkinson’s disease; PD-D: Parkinson’s disease dementia; COG: cognitive; UPDRS:Unified Parkinson Disease 
Rating Scale; DAD: Disability Alzheimer Disease Scale; BDI: Deck Depression Inventory; MMSE: Mini Mental Status Exam; FAB: Frontal Assessment Battery; 
RAVLT: Rey Audictory Learning Test; FCR: Figure Complex of Rey; TMT: Trail Making Test.
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DISCUSSION
Our findings showed that the prevalence of PD-D 
was about 23.8%, corroborating previous studies that 
place prevalence of PD-D in the PD population at ap-
proximately 30%. In addition, older current age and 
older age at onset of disease, lower educational level and 
higher scores on the Hoehn & Yahr and Schwab and Eng-
land scores were associated with PD-D, but only cur-
rent age and Hoehn & Yahr score predicted the devel-
opment of PD-D. 
Comparison between diagnostic criteria (Level II) 
and clinical procedures (Level I) for PD-D revealed that 
Level II had good discrimination in the detection of 
PD-D, whereas Level I criteria had lower specificity and 
greater sensitivity as a diagnostic procedure for PD-D. 
We hypothesized that lower sensitivity with Level I cri-
teria could be related to the adoption of a MMSE cutoff 
of less than 26. This was confirmed when the data were 
reanalyzed after taking into account educational level 
cutoff scores on the MMSE, which revealed that 49% of 
the sample had an impaired score. This suggests that the 
MMSE cutoff proposed by MDS Level I criteria could 
be affected by educational level and not considering ed-
ucational level leads to a false-negative PD-D diagnosis.
Although the MMSE has been recommended as a 
useful tool in identifying cognitively impaired patients 
with PD6, some studies have called into question its accu-
racy in detecting cognitive impairments in PD25. There-
fore, the comparison of cognitive performance of pa-
tients with normal cognition according to MMSE to 
other instruments (SCOPA-COG26 and MoCA27) reve-
lead that MMSE is less insensitive to detect cognitive im-
pairments due to PD. 
We also found that few patients had cognitive im-
pairment severe enough to impair the ability to inde-
pendently organize their daily distribution of antipar-
kinsonism medication (Pill Questionnaire), which was 
used as a functional measure proposed by MDS Level 
I criteria. Twelve of the 20 PD-D subjects (60%) were 
able to take their antiparkinsonism pills independent of 
caregiver supervision despite the fact that functional im-
pairment was noted in the DAD scale and only 8 PD-D 
patients (40%) had functional impairment observed by 
both the Pill Questionnaire and the DAD scale. For PD 
patients without dementia, functional impairment was 
observed by the DAD scale in 5 subjects (8%) who had 
intact cognitive functioning as measured by the Pill 
Questionnaire, whereas only 1 patient reported an in-
ability to manage their medications despite having intact 
functional abilities. Higher difficulties reported in the Pill 
Questionnaire concerned the ability of the patient to de-
scribe their list of drugs and their doses without assis-
tance followed by their ability to take their pills without 
supervision. In PD-D patients, the sequence of difficul-
ties was the opposite. More patients required a care-
giver to help them take their pills than those who had 
difficulties in describing their pill schedule. Neverthe-
less, on the DAD scale, we found that the PD-D group 
had much greater impairments with instrumental ADLs 
(telephoning, going on an outing, taking care of finances 
and correspondences and leisure activities) than with 
basic ADLs (i.e., dressing) in comparison to the non-de-
mented group. However, both groups were able to take 
their medications. Previous studies found that the asso-
ciation between cognition and ADL depends substan-
tially on instrumental ADLs in PD28 and the presence of 
PD-D greatly impairs the ability to perform ADLs29. Our 
results show that the PD-D group had impairment on 
some cognitive dimensions related to disabilities in ADL, 
but not in all of them. The initiation to take antiparkin-
sonism pills remained intact, whereas planning and or-
ganizing (measured by correct description of doses and 
drugs without caregiver supervision) were affected. Thus, 
it is possible that the ability to remember taking antipar-
kinsonism pills will be the last domain impaired because 
taking the medications leads to a reduction of motor 
symptons. To our knowledge, this is the first study that 
adopted diagnostic procedures and criteria for PD-D as 
recommended by the MDS. Our results confirm a re-
cent study28 that showed that some individuals who are 
not demented, according to MDS criteria, may have sig-
nificant disability on the basis of cognitive dysfunction.
As expected, worse performance on all neuropsycho-
logical tests was observed in the PD-D group. Moreover, 
confirming previous studies, we found that age , age at 
onset of disease, more advanced disease (higher Hoehn 
& Yahr score) poorer scores on the Schawb and Eng-
land scale were related to PD-D9. Our sample had a low 
education level overall (4.72±3.60 years), but the PD-D 
group had a lower education level (2.18±1.42 years). 
When we conducted a non-linear regression analysis, 
age and severity of disease (Hoehn & Yahr score), but 
not years of schooling, appeared as predictors of PD-D. 
Although this study demonstrated that prevalence 
rates of PD-D varied depending on the diagnostic pro-
cedure adopted and that clinical characteristics, such as 
age and severity of disease, are predictors of PD-D, it has 
some limitations. First, the sample was not representa-
tive of the entire population of PD patients. Our sample 
was only representative of the hospital-based popula-
tion, which may be subject to a selection bias. Second, al-
though the choice of neuropsychological tests was based 
on recommendations from the MDS task force6, some 
tests were influenced by education level (Phonemic Flu-
ency Verbal - FAS, Stroop Color and Trail Making Tests) 
and motor impairments (Figure Complex of Rey, Trail 
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Making Test and Visual Reproduction Test), leading to 
a possible underperformance by patients in our sample 
who had a low education level, 9% of which were illit-
erate. Third, it is important to note that despite mul-
tiple predictors considered in the present analyses, we 
did not assess some neuropsychiatric functions (such as 
apathy and visual hallucination). On other hand, one of 
the strengths of this study is that, to our knowledge, ours 
is the first study to compare the incidence of PD-D ac-
cording to diagnostic procedures and clinical diagnostic 
criteria proposed by the MDS. Standardized criteria for 
dementia and neuropsychological evaluations were per-
formed blind to the neurological assessment. 
In conclusion, our results indicate that the Level I 
MDS diagnostic criteria has low sensitivity and speci-
ficity in detecting PD-D in comparison to Level II cri-
teria. Moreover, current age and higher Hoehn & Yahr 
scores were predictors of PD-D and our findings have 
implications for patient management and clinical prac-
tice. Patients with PD, particularly those with risk factors 
for developing PD-D, should be regularly submitted to 
brief cognitive assessment and carefully monitored for 
progression of dementia.
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